Aurobindo Pharma Share Price in Focus; USFDA Issues One Observation for Telangana Facility

Aurobindo Pharma has completed a US FDA inspection at Unit-II of Apitoria Pharma Private Limited in Telangana, as per the exchange filing. The inspection started on September 7, 2026, and concluded on September 15, 2026. 

The facility is located at Gaddapotharam in the Kazipally Industrial Area of Sangareddy district and is used for API manufacturing. Apitoria Pharma is a wholly owned subsidiary of Aurobindo Pharma.  

Inspection Ends at Unit-II 

The inspection covered the Unit-II facility over the nine-day period. Aurobindo Pharma has now formally informed the stock exchanges about its completion. 

The company said the inspection concluded with one observation, which it described as procedural in nature.  

Company To Respond 

Aurobindo Pharma said it will respond to the US FDA within the stipulated timeline following the observation. 

The company also said it remains focused on maintaining its standards across its manufacturing facilities.  

Apitoria's Telangana Facility 

Unit-II is part of Apitoria Pharma's manufacturing operations in Telangana. The facility is situated in the Kazipally Industrial Area, Jinnaram Mandal, in Sangareddy district. 

The latest inspection therefore relates specifically to this API manufacturing site rather than the company's wider manufacturing network.  

Read More: Praj Industries Share Price in Focus; Signs Bio-IBA Commercialisation Agreement with Gevo! 

Aurobindo Pharma Share Price Performance  

As of 16 September 2026, at 2:17 PM, Aurobindo Pharma Ltd share price is trading at ₹1,648.40 per share, reflecting a decline of 0.70% from the previous trading session. 

Conclusion 

The US FDA inspection at Apitoria Pharma's Unit-II facility in Telangana has concluded, with Aurobindo Pharma set to respond to the observation within the stipulated timeline. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.